Antiviral capacity of the early CD8 T-cell response is predictive of natural control of SIV infection: Learning in vivo dynamics using ex vivo data

PLoS Comput Biol. 2024 Sep 10;20(9):e1012434. doi: 10.1371/journal.pcbi.1012434. eCollection 2024 Sep.

Abstract

While most individuals suffer progressive disease following HIV infection, a small fraction spontaneously controls the infection. Although CD8 T-cells have been implicated in this natural control, their mechanistic roles are yet to be established. Here, we combined mathematical modeling and analysis of previously published data from 16 SIV-infected macaques, of which 12 were natural controllers, to elucidate the role of CD8 T-cells in natural control. For each macaque, we considered, in addition to the canonical in vivo plasma viral load and SIV DNA data, longitudinal ex vivo measurements of the virus suppressive capacity of CD8 T-cells. Available mathematical models do not allow analysis of such combined in vivo-ex vivo datasets. We explicitly modeled the ex vivo assay, derived analytical approximations that link the ex vivo measurements with the in vivo effector function of CD8-T cells, and integrated them with an in vivo model of virus dynamics, thus developing a new learning framework that enabled the analysis. Our model fit the data well and estimated the recruitment rate and/or maximal killing rate of CD8 T-cells to be up to 2-fold higher in controllers than non-controllers (p = 0.013). Importantly, the cumulative suppressive capacity of CD8 T-cells over the first 4-6 weeks of infection was associated with virus control (Spearman's ρ = -0.51; p = 0.05). Thus, our analysis identified the early cumulative suppressive capacity of CD8 T-cells as a predictor of natural control. Furthermore, simulating a large virtual population, our model quantified the minimum capacity of this early CD8 T-cell response necessary for long-term control. Our study presents new, quantitative insights into the role of CD8 T-cells in the natural control of HIV infection and has implications for remission strategies.

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes* / immunology
  • Computational Biology
  • Macaca mulatta
  • Models, Immunological
  • Simian Acquired Immunodeficiency Syndrome* / immunology
  • Simian Acquired Immunodeficiency Syndrome* / virology
  • Simian Immunodeficiency Virus* / immunology
  • Simian Immunodeficiency Virus* / physiology
  • Viral Load*

Grants and funding

This study was supported by IFCPAR/CEFIPRA Project #64T4-2 (N.M.D., J.G., A.S.-C.). The experimental study was funded by the French National Agency of AIDS and Viral Hepatitis Research (ANRS) and by MSDAvenir (C.P., A.M., V.A.-F., R.D.-D., N.D.-B., R.L.G., C.R., Br.V., A.S.-C.). Additional support was provided by the Programme Investissements d’Avenir (PIA), managed by the ANR under reference ANR‐11‐INBS‐0008, funding the Infectious Disease Models and Innovative Therapies (IDMIT, Fontenay‐aux‐Roses, France) infrastructure (C.P., A.M., V.A.-F., R.D.-D., N.D.-B., R.L.G., C.R., Br.V., A.S.-C.), and ANR‐10‐EQPX‐02‐01, funding the FlowCyTech Facility (IDMIT, Fontenay‐aux‐Roses, France) (C.P., A.M., V.A.-F., R.D.-D., N.D.-B., R.L.G., C.R., Br.V., A.S.-C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.